3.21

0.62% -0.02

After Hours: 3.21

Dare Bioscience Inc (DARE)

Overview News Price History Financials Discussions Forecast Stock Split

Dare Bioscience Inc stock is traded at $3.21, with a volume of 17,962. It is down -0.62% in the last 24 hours and down -0.62% over the past month. Dare Bioscience Inc is a biopharmaceutical company committed to advancing innovative products for women's health. The company identifies, develops and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in advanced clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.

Previous Close:

$3.23

Open:

$3.21

24h Volume:

17,962

Relative Volume:

0.39

Market Cap:

$27.93M

Revenue:

Net Income/Loss:

$-30.16M

P/E Ratio:

-9.4412

EPS:

-0.34

Net Cash Flow:

$-39.49M

1W Performance:

-1.23%

1M Performance:

-0.62%

6M Performance:

-6.14%

1Y Performance:

+876.57%

1-Day Range:

$3.21

$3.26

1-Week Range:

$3.20

$3.3228

52-Week Range:

$0.28

$4.60

Dare Bioscience Inc Stock (DARE) Company Profile

Name

Dare Bioscience Inc

Sector

Healthcare (1174)

Industry

Biotechnology (678)

Phone

858-926-7655

Address

3655 NOBEL DRIVE, SAN DIEGO, CA

Employee

Twitter

@DareBioscience

Next Earnings Date

2024-11-07

Latest SEC Filings

DARE's Discussions on Twitter

Compare DARE with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
DARE Dare Bioscience Inc	3.21	27.93M	0	-30.16M	-39.49M	-0.34
VRTX Vertex Pharmaceuticals Inc	438.40	112.90B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	683.08	75.06B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	665.68	40.45B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	277.16	35.75B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	120.88	28.98B	3.30B	-501.07M	1.03B	-2.1146

Dare Bioscience Inc Stock (DARE) Latest News

Jan 28, 2025

Daré Bioscience (NASDAQ:DARE) Shares Cross Below 200-Day Moving Average – Time to Sell? - Defense World

Jan 28, 2025

Jan 20, 2025

Daré Bioscience (NASDAQ:DARE) Prepares to Share Corporate Presentation on January 13, 2025 - Defense World

Jan 20, 2025

Jan 14, 2025

Geode Capital Management LLC Decreases Stock Holdings in Daré Bioscience, Inc. (NASDAQ:DARE) - Defense World

Jan 14, 2025

Daré Bioscience (NASDAQ:DARE) Share Price Crosses Above Fifty Day Moving Average – Time to Sell? - Defense World

Jan 14, 2025

Jan 13, 2025

Daré Bioscience Announces New Corporate Presentation - TipRanks

Jan 13, 2025

Jan 09, 2025

Daré Bioscience to Participate in the Women's Health Series at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times

Jan 09, 2025

Daré Bioscience to Participate in the Women’s Health Series at the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewswire

Jan 09, 2025

Daré Bioscience CEO to Spotlight Women's Health Innovation at J.P. Morgan Healthcare Conference - StockTitan

Jan 09, 2025

Jan 05, 2025

State Street Corp Lowers Stake in Daré Bioscience, Inc. (NASDAQ:DARE) - Defense World

Jan 05, 2025

Jan 02, 2025

Daré Bioscience, Inc. and ARPA-H Ring the Nasdaq Stock Market Closing Bell - Nasdaq

Jan 02, 2025

Daré Bioscience, Inc. and ARPA-H Ring the Closing Bell - Nasdaq

Jan 02, 2025

Daré Bioscience (NASDAQ:DARE) Shares Pass Below 200-Day Moving Average – Time to Sell? - Defense World

Jan 02, 2025

Dec 25, 2024

Daré Bioscience (NASDAQ:DARE) Share Price Passes Below Two Hundred Day Moving Average – Here’s What Happened - Defense World

Dec 25, 2024

Dec 19, 2024

DARE Stock Touches 52-Week Low at $3.04 Amid Market Challenges - Investing.com

Dec 19, 2024

Dec 18, 2024

Daré Bioscience Announces Phase 3 Plans for Sildenafil Cream Development to Address Female Sexual Arousal Disorder - Defense World

Dec 18, 2024

Dec 16, 2024

Daré Bioscience to initiate phase 3 study of FSAD treatment - Investing.com

Dec 16, 2024

Daré Bioscience Announces Phase 3 Plans for Sildenafil Cream, 3.6%, in the Treatment of Female Sexual Arousal Disorder (FSAD) - The Manila Times

Dec 16, 2024

Daré Bioscience Announces Phase 3 Plans for Sildenafil - GlobeNewswire

Dec 16, 2024

Daré Bioscience Advances First-Ever FSAD Treatment: Phase 3 Trial Set for Breakthrough Female Sexual Health Drug - StockTitan

Dec 16, 2024

Dec 10, 2024

Daré Bioscience Announces Publication in Sexual Medicine of - GlobeNewswire

Dec 10, 2024

Daré Bioscience's Sildenafil Cream Shows Promising Clinical Data for Female Sexual Health Treatment - StockTitan

Dec 10, 2024

Dec 05, 2024

Daré Bioscience receives $2.5 million for contraceptive tech By Investing.com - Investing.com Canada

Dec 05, 2024

Dec 04, 2024

Daré Bioscience receives $2.5 million for contraceptive tech - Investing.com India

Dec 04, 2024

DAREDare Bioscience, Inc. Latest Stock News & Market Updates - StockTitan

Dec 04, 2024

Daré Bioscience Announces $2.5 Million Grant Funding - GlobeNewswire

Dec 04, 2024

Daré Bioscience Announces $2.5 Million Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1 - The Manila Times

Dec 04, 2024

Daré Bioscience Advances Revolutionary Wireless Contraceptive Tech With $2.5M Grant Milestone - StockTitan

Dec 04, 2024

Nov 27, 2024

Dare Bioscience Q3 2024 Earnings Preview - MSN

Nov 27, 2024

Nov 26, 2024

Analyzing Vistagen Therapeutics (NASDAQ:VTGN) and Daré Bioscience (NASDAQ:DARE) - Defense World

Nov 26, 2024

Nov 23, 2024

Daré Bioscience, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 23, 2024

Nov 20, 2024